Selective V1a Receptor Antagonists for Anxiety and Circadian Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions associated with V1a receptor modulation, such as anxiety, depressive disorders, and autistic spectrum disorders, often have side effects due to non-selective action on vasopressin receptors, and there is a lack of effective biological pharmaceuticals for circadian rhythm-related disorders like jet lag.
Innovation Solution
Development of heteroaryl-methyl substituted triazoles that act as selective V1a receptor antagonists, which can be administered to modulate the V1a receptor, thereby providing therapeutic benefits for various conditions without the unwanted side effects associated with non-selective vasopressin receptor activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If non-selective vasopressin receptor antagonists are used, then broad spectrum activity against multiple vasopressin receptors is achieved, but off-target side effects increase
Solution Approach 1:
The patent segments the vasopressin receptor antagonism into selective sub-types by designing compounds that specifically target the V1a receptor while sparing other vasopressin receptor subtypes. This is achieved through specific molecular structure design (formula I with defined substituents) that provides selective binding affinity for V1a, thereby maintaining versatility in treating V1a-mediated conditions while eliminating off-target effects on other receptors.
Solution Approach 2:
The invention applies local quality by creating compounds with specific structural features (heteroaryl-methyl substituted triazole core with defined R1, R2, R3, R4, R5, R6, R7, R8 substituents) that confer selective affinity for the V1a receptor binding site. This localized molecular design ensures the drug interacts specifically with V1a receptor structures, providing targeted therapeutic action without affecting other receptor types.
2Object-affected harmful factors
If selective V1a receptor antagonists are developed, then off-target side effects are reduced, but therapeutic coverage for multiple vasopressin-mediated conditions is limited
Solution Approach 1:
The patent achieves universality by demonstrating that selective V1a receptor antagonism can treat multiple diverse conditions through a single mechanism of action. The compounds of formula I are shown to be effective for anxiety, depressive disorders, autistic spectrum disorders, and circadian rhythm disorders, all mediated through V1a receptor pathways. This multi-functional approach allows one selective compound class to address various psychiatric and neurological conditions without requiring different receptor targets.
3Reliability
If existing anxiolytic treatments are used, then anxiety and depressive symptoms are treated, but side effects occur due to non-selective receptor action
Solution Approach 1:
The invention extracts the desired therapeutic effect from the complex mixture of receptor interactions by isolating and targeting only the V1a receptor pathway. Instead of using non-selective compounds that affect multiple receptors, the patent designs molecules that specifically bind to and block V1a receptors, thereby extracting the anxiolytic and antidepressant effects from their V1a antagonism while leaving other receptor systems undisturbed, thus eliminating associated side effects.
Data Source
AI summary
The invention provides novel compounds having the general formula I wherein R and X are as defined herein, compositions including the compounds and methods of using the compounds.